Pleural Catheters Versus Thoracoscopic Pleurodesis

2014-08-27 03:13:54 | BioPortfolio


The goal of this clinical research study is to compare 2 different methods for treating a pleural effusion. Researchers also want to learn how the treatment received affects quality of life (ability to do the things patients like to do and how happy patient feels).


If you agree to take part in this study, you will fill out a questionnaire called the M. D. Anderson Symptom Inventory (MDASI) before your scheduled pleural effusion treatment procedure and again each time you return to the clinic for a follow-up visit. The MDASI has 19 questions about the possible symptoms caused by the disease, which you will rate on a scale of 1-10. The MDASI will take about 5 minutes to complete each time.

Follow-Up Phone Calls:

After you have completed your final follow-up treatment visit, a computer system will call you at home 1 time each month and ask you the same questions that you answered on the MDASI at your clinic visits. The phone call should last about 5 minutes each time.

Length of Study:

You will continue to complete the MDASI in the clinic for as long as you have follow-up treatments. You will continue to complete the MDASI follow-up phone calls for the rest of your life.

Your information will be stored in a password-protected database for use in future research related to cancer for up to 5 years after the study is completed.

Before any of your information that is stored in the database can be used for research, the people doing the research must get specific approval from the Institutional Review Board (IRB) of M. D. Anderson. The IRB is a committee made up of doctors, researchers, and members of the community. The IRB is responsible for protecting the participants involved in research studies and making sure all research is done in a safe and ethical manner. All research done at M. D. Anderson, including research involving your data from this bank, must first be approved by the IRB.

Your information will be given a code number so that none of your personal identifying information will be directly linked to your information. Only the researcher in charge of the database will have access to the code numbers and be able to link the information in the database back to you. Other researchers who use the database will not be able to link your information or file back to you.

This is an investigational study. Up to 245 participants will be enrolled at M. D. Anderson.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Lung Cancer


MDASI Questionnaire


UT MD Anderson Cancer Center
United States




M.D. Anderson Cancer Center

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:13:54-0400

Clinical Trials [3477 Associated Clinical Trials listed on BioPortfolio]

Symptom Burden in Chronic Myeloid Leukemia (CML)

The objective of this study is to measure and delineate the symptom burden experienced by patients with chronic myeloid leukemia (CML). The Primary Aim is to develop and validate an M. D....

M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) Symptom Management Program

Primary Objective: To determine if there is a reduction in the mean symptom severity scores for the heart failure specific symptom items between baseline and at the end of three months be...

Perioperative Symptom Study of Lung Cancer

Investigators propose a prospective cohort study to develop and validate essential technical parameters for establishing the perioperative symptom management cohort in patients with lung c...

Measurement of Pain and Other Symptoms of Non-Small Cell Lung Cancer (NSCLC) Patients Following Thoracic Surgery

Primary Objectives: - To longitudinally assess the natural history of symptoms (prevalence, severity, patterns of symptoms, and the relationship of physical and psychological dist...

M.D. Anderson Symptom Inventory (MDASI) Validation Study in Cancer Patients

Primary Objectives: 1. To examine how the M.D. Anderson Inventory (MDASI) performs in various sample populations including community dwelling adults and patients who have different...

PubMed Articles [16672 Associated PubMed Articles listed on BioPortfolio]

Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma.

Lung cancer is one of the deadliest malignancies. The immune checkpoint-blockade (ICB) tumor therapy has led to striking improvement of long-term survival for some lung cancer patients. However, the r...

Lung Cancer: One Disease or Many.

Lung cancer is classified as a single entity comprised of multiple histological subtypes. But how similar are these subtypes on a genetic level? This paper aims to address this question through a conc...

Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study.

The relative risk of lung cancer decreases with years since quitting (YSQ) smoking, but risk beyond 25 YSQ remains unclear. Current lung cancer screening guidelines, which exclude smokers with more th...

Lung Cancer Health Disparities.

Compared with all other racial and ethnic groups in the U.S., African Americans are disproportionally affected by lung cancer, both in terms of incidence and survival. It is likely that smoking, as th...

Lung Cancer Screening in the Community Setting.

Lung cancer has high incidence and high mortality burden particularly since it is typically diagnosed in later stages. The National Lung Screening Trial demonstrated a lung cancer specific mortality b...

Medical and Biotech [MESH] Definitions

Self report questionnaire which yields 16 scores on personality traits, such as reserved vs. outgoing, humble vs. assertive, etc.

Tumors or cancer of the LUNG.

Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.

Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

More From BioPortfolio on "Pleural Catheters Versus Thoracoscopic Pleurodesis"

Quick Search


Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Searches Linking to this Trial